Articles by Catherine Coombs, MD
The newer agents have distinguished themselves especially by having safety profiles superior to ibrutinib.
Dr. Coombs discussed time limited therapies and the phase III AMPLIFY trial of acalabrutinib plus venetoclax in CLL.
Catherine Coombs, MD, outlined some of her research into the solid tumor microenvironment, particularly in prostate cancer.
Drs. Nabhan, Coombs, and Danilov discussed the BRUIN, TRANSCEND, and FLAIR trials in CLL.
Dr. Coombs presented the study and its findings during the 2023 American Society of Clinical Oncology Annual Meeting.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.